Global mRNA Vaccines and Therapeutics Market - 2025 - 2032

Global mRNA Vaccines and Therapeutics Market - 2025 - 2032

The global mRNA Vaccines and Therapeutics market reached US$ 410 million in 2024 and is expected to reach US$ 503 million by 2032, growing at a CAGR of 9.0% during the forecast period 2025-2032.

mRNA vaccines and therapeutics represent a groundbreaking advancement in biotechnology, offering innovative solutions for a wide range of infectious diseases, genetic disorders, and cancer. Unlike traditional vaccines, which use weakened or inactivated virus particles to trigger immune responses, mRNA vaccines work by instructing cells to produce a protein that mimics the pathogen, thereby stimulating the immune system.

The mRNA vaccines and therapeutics market has experienced rapid growth, fueled by the increased adoption of mRNA-based vaccines for COVID-19 and the promising potential of mRNA technology in treating chronic and complex diseases. With the ability to quickly adapt and target specific pathogens or disease mechanisms, mRNA offers a flexible platform for developing vaccines and therapies with fewer side effects compared to traditional treatments.

Market Dynamics: Drivers & Restraints

Growing cases of chronic diseases

The rising prevalence of chronic diseases such as cancer, cardiovascular diseases and other autoimmune diseases is expected to drive the mRNA vaccines and therapeutics market growth. There is a growing demand for vaccines and therapeutics with the growing awareness of the increasing incidence of cancer cases. For instance, according to the National Cancer Institute in 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million.

As chronic diseases continue to place a significant strain on global healthcare systems, the demand for more effective treatments and preventative solutions is steadily increasing. mRNA technology, which has already proven its effectiveness in COVID-19 vaccines, holds great promise for developing targeted therapies for conditions like cancer and other chronic illnesses.

By utilizing mRNA’s ability to direct cells to produce specific proteins, researchers have the potential to create vaccines and therapeutics that address the root causes of diseases, offering more targeted treatments with fewer side effects. This growing need for advanced, personalized approaches to managing chronic diseases is driving the expansion of the mRNA-based therapeutics market, positioning it as one of the fastest-growing areas in modern medicine.

Competition from Alternative Vaccines and Therapeutics

Competition from alternative technologies could hinder the growth of the mRNA vaccines and therapeutics market by offering potentially safer or more established solutions. For instance, protein subunit vaccines, viral vector-based vaccines, and monoclonal antibodies are alternative platforms that have been used successfully in various treatments and may be preferred by some healthcare providers or patients due to their familiarity.

These alternatives may also present fewer concerns related to safety, storage requirements, or production challenges, making them more appealing in certain situations. As a result, the market share for mRNA-based products could face limitations, especially if these competing technologies prove more efficient, cost-effective, or widely accepted in the long run.

Segment Analysis

The global mRNA Vaccines and Therapeutics market is segmented based on product type, application, end-user, and region.

Type:

Prophylactic vaccines segment is expected to dominate the global mRNA vaccines and therapeutics market share

The prophylactic vaccines segment is poised to dominate the mRNA vaccines and therapeutics market, fueled by the proven success of mRNA technology in addressing infectious diseases, particularly with COVID-19 vaccines. The inherent speed and flexibility of mRNA platforms enable rapid development and scalable production, making them invaluable in responding to emerging health threats and pandemics. This capability has fostered strong confidence in mRNA vaccines, known for delivering robust, long-lasting immunity and their adaptability to new pathogens.

Beyond COVID-19, the development of mRNA vaccines for infectious diseases like influenza and HIV further positions this technology as a key solution for global health challenges. As the approval and widespread adoption of mRNA-based vaccines continue to expand, the prophylactic vaccines segment is set to maintain a dominant position in the market, driven by the technology's effectiveness and its potential to address a wide range of infectious diseases.

Geographical Analysis

North America is expected to hold a significant position in the global mRNA vaccines and therapeutics market share

North America is expected to hold a significant position in the global mRNA vaccines and therapeutics market due to several key factors. Several pharmaceutical companies and biotech firms have been at the forefront of mRNA vaccine development, especially in response to the COVID-19 pandemic. These companies' expertise, along with substantial investment in mRNA technology, has positioned North America as a global leader in both research and commercialization of mRNA-based therapies.

For instance, in May 2024, Moderna Inc. received the FDA approval for the mRNA RSV vaccine, which will be marketed as mRESVIA. The novel mRNA RSV vaccine is indicated to protect adults aged 60 years and older from lower respiratory tract disease (LRTD) caused by RSV infection. The approval was granted under a breakthrough therapy designation, marking Moderna’s second FDA-approved mRNA vaccine.

Additionally, North America benefits from a robust regulatory framework, with agencies such as the U.S. FDA and Health Canada offering significant support in the approval and distribution of mRNA vaccines and therapeutics. This conducive regulatory environment accelerates the approval process, ensuring faster market access and allowing companies to introduce innovative treatments with greater efficiency.

Moreover, the region has robust funding and clinical organizations involved in the development of several vaccines and therapeutics. Several clinical trials are being conducted in the region by companies and organizations which increases the product portfolio and meets the rising demand for vaccines. For instance, in February 2023, Pfizer Inc. and BioNTech SE initiated Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.

In December 2022, Moderna, Inc. and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.

Competitive Landscape

The major global players in the mRNA vaccines and therapeutics market include AstraZeneca, Pfizer Inc., Moderna, Inc., BioNTech SE., Arcturus Therapeutics, Inc., CureVac SE, Sanofi, and etherna among others.

Key Developments
• In September 2024, ME Therapeutics Holdings Inc. announced the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc.
• In April 2024, Sanofi signed a master service agreement with IDT Australia focusing on the preclinical formulation development and current Good Manufacturing Practice (cGMP) manufacturing of its messenger RNA (mRNA) vaccines.
• In April 2024, VBI Vaccines Inc. expanded its collaboration with the government of Canada, supported by a funding contribution from the government’s Strategic Innovation Fund (SIF). Under the new agreement, the remaining CAD$28 million of funding available under the previously committed CAD$56 million will be directed toward the development of VBI’s proprietary MLE platform, a next-generation version of the Company’s particulate, enveloped virus-like particle (“eVLP”) vaccine technology that enables the coding of eVLPs using messenger RNA (“mRNA”).

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global MRNA Vaccines and Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.